Drug Profile
Research programme: intraocular therapeutics - ImprimisRx
Alternative Names: Epinephrine/lidocaine; Go Dropless; IPI-140; Lidocaine/epinephrine; Lidocaine/phenylephrine combination; Lyophilized epinephrine combination; Moxifloxacin/triamcinolone; Shugarcaine combination; Triamcinolone/moxifloxacin; Triamcinolone/vancomycin; TriMox; TriMox/vancomycin; TriMoxi; TriMoxi/vancomycin; Vancomycin/moxifloxacin/triamcinoloneLatest Information Update: 14 Jan 2019
Price :
$50
*
At a glance
- Originator Eye Care Northwest; Novel Drug Solutions
- Developer ImprimisRx
- Class Acetanilides; Azabicyclo compounds; Catecholamines; Cyclopropanes; Ethanolamines; Fluorinated steroids; Fluoroquinolones; Glucocorticoids; Glycopeptides; Piperidines; Pregnadienes; Pyrrolidines; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postoperative infections; Postoperative inflammation
Most Recent Events
- 31 Dec 2018 Imprimis Pharmaceuticals changed its name to Harrow Health and added all ophthalmology business to its subsidiary ImprimisRx
- 18 Nov 2014 Discontinued - Preclinical for Postoperative infections (Prevention) and Postoperative inflammation (Prevention) in USA (Intraocular)
- 18 Nov 2014 Discontinued - Preclinical for Postoperative inflammation (Prevention) in USA (Intraocular)